Business
Ingevity makes specialty chemicals and activated carbon products.
Ingevity contracted revenue, reported a net loss, generated positive free cash flow at a 35.9% operating margin. A reported loss diverged from high operating margin and strong free cash flow, indicating material below-line or special items.
The read at a glance✓ Audited against SEC data
- Growth — Revenue declined 2.7%Watch
- Profitability — The net loss narrowed from $430.3M to $167.1MOK
- Cash flow — Free cash flow grew 436.3% to $273.5M from $51MOK
- Margins — Operating margin expanded 37 bps to 35.86%OK
- Accounting — A reported loss diverged from high operating margin and strong free cash flow, indicating material below-line or special itemsNote
- Insiders — 0 purchases and 1 salesNote
Where the revenue comes from
Fiscal 2025, as Ingevity Corp reports it. History and quarterly detail are in the app.
- Performance Materials$606.9M
- Performance Chemicals$400.5M
- Advanced Polymer Technologies$160.2M
Leadership changes
From Ingevity Corp's own filings, the day they're filed.
- Phillip J. Platt · President · appointmenteff. 2026-05-01
- Daniel F. Sansone · directors · departureeff. 2026-02-17
- Richard White · President · departureeff. 2026-01-01
Latest filings
- 10-Q · Quarterly report2026-07-30
- 8-K · Company announcement2026-07-29
- 8-K · Company announcement2026-06-24
- 10-Q · Quarterly report2026-05-07
- 8-K · Company announcement2026-05-06
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Ingevity Corp, every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.